---
layout: default
title: Cetuximab
parent: Model Prediction Only (L5)
nav_order: 168
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-14
description: "Cetuximab: predicted new indication Non-seminomatous lesion (evidence level L5). Approved use: Colorectal cancer and squamous cell carcinoma…"
monitor_inn: "Cetuximab"
predicted_indications: ["non-seminomatous lesion", "chondroid hamartoma", "bronchial adenomas/carcinoids childhood", "ductal or ductular proliferation", "tumor of testis and paratestis", "odontogenic cyst", "thyroglossal duct cyst", "epiglottis neoplasm", "cystic neoplasm", "pre-malignant neoplasm"]
---

# Cetuximab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Cetuximab: From Colorectal Cancer to Non-Seminomatous Lesion
{: .text-alpha }

## One-Sentence Summary

Cetuximab is an anti-EGFR monoclonal antibody, originally used to treat colorectal cancer and squamous cell carcinoma of the head and neck.
The TxGNN model predicts it may be effective for a **non-seminomatous lesion**, but **no clinical trials and no publications** were found to support this prediction. It is a model-only signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Colorectal cancer and squamous cell carcinoma, including pharyngeal and laryngeal types (the licence records in India carry no indication text) |
| Predicted New Indication | Non-seminomatous lesion |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| India Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, cetuximab is an antibody that targets the epidermal growth factor receptor (EGFR). Its efficacy in EGFR-expressing metastatic colorectal cancer and in squamous cell head and neck cancers is established.

Mechanistically, it could be applicable to another tumour type only if that tumour depends on EGFR signalling. The data compiled for this report contain no evidence of EGFR dependence in non-seminomatous germ cell lesions. The high TxGNN score therefore reflects a statistical pattern in the knowledge graph, not a demonstrated biological rationale. The relationship between the original and predicted indications has not been assessed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| 73420 | Erbitux 500mg Infusion | Bottle of 50 ml infusion | Merck Ltd |
| 73829 | Erbitux 100mg Infusion | Bottle of 50 ml infusion | Merck Ltd |
| 74511 | Erbitux 5mg/ml Solution for Infusion | Bottle of 20 ml solution for infusion | Merck Ltd |

All three registrations are valid single-ingredient products, and none have been cancelled. The licence records contain no approved-indication text.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Infusion reactions, skin toxicity and electrolytes (especially magnesium) are the main concerns noted in the compiled data. For the full monitoring schedule, please refer to the package insert. |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

- **Drug Interactions**: 19 interactions were identified in the interaction database, mostly Moderate.
  - **Major**: aminolevulinic acid, thalidomide.
  - **Moderate (selected)**: platinum agents (cisplatin, carboplatin, oxaliplatin), fluoropyrimidines (fluorouracil, capecitabine), proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole), idelalisib, verteporfin, methoxsalen and omacetaxine mepesuccinate.

Please refer to the package insert for warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on model output alone (L5), with no trials, no literature and no supporting mechanism for non-seminomatous lesions. Cetuximab's known risks, such as infusion reactions and skin toxicity, cannot be justified without efficacy evidence.

**To proceed, the following is needed:**
- Mechanism of action data and a biological rationale showing EGFR dependence in non-seminomatous germ cell lesions
- Preclinical or clinical evidence in the predicted indication
- Package insert warnings and contraindications from the India label
- A clear definition of the predicted disease term, which is currently non-specific

**Note on other predictions:** Among the other predicted indications compiled for this drug, "pre-malignant neoplasm" has the strongest support (L2). It includes a completed Phase II single-agent cetuximab trial in high-risk pre-malignant upper aerodigestive lesions (NCT00524017). It would be a more productive lead to evaluate first, with the caveat that efficacy results from that trial are not yet available in the compiled data.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

